Comparison of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and multi-parametric magnetic resonance imaging (MRI) in the evaluation of tumor extension of primary prostate cancer

Chen, Mengxia; Zhang, Qing; Zhang, Chengwei; Zhou, Yihua; Zhao, Xiaozhi; Fu, Yao; Gao, Jie; Zhang, Bing; Wang, Feng; Qiu, Xuefeng; H, Guo

doi:10.21037/tau.2020.03.06

Cited by 27 publications

(38 citation statements)

References 25 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our previous study indicates improved sensitivity of PSMA-ligand PET/CT in describing intraprostatic tumor lesions compared with multiparametric magnetic resonance Imaging (mpMRI) (12). In addition, increased PSMA uptake on PSMA-ligand PET/CT has been indicated to be positively correlates with prostate cancer aggressiveness and adverse pathologic features in our previous studies (13,14), making PSMA-ligand PET/CT a potential tool to predict BCR following RP. Nonetheless, current models for prediction of BCR are mostly based on clinical and pathologic variables.…”

Section: Introductionmentioning

confidence: 94%

Prediction of Biochemical Recurrence After Radical Prostatectomy Based on Preoperative 68Ga-PSMA-11 PET/CT

et al. 2021

Self Cite

View full text Add to dashboard Cite

PurposeThis study was designed to investigate the prognostic role of preoperative 68Ga-PSMA-11 PET/CT in predicting biochemical recurrence (BCR) of localized prostate cancer (PCa) after radical prostatectomy (RP).MethodsA total of 77 biopsy-confirmed PCa patients with 68Ga-PSMA-11 PET/CT prior to RP were included. A PSMA-ligand PET/CT-based risk model with SUVmax, maximum diameter of the index tumor and T stage was developed for prediction of 2-year BCR using Cox regression analysis. Also, the efficacy of the developed risk model was compared with European Association of Urology risk stratification (D’Amico) and the Cancer of the Prostate Risk Assessment (CAPRA) score. C-index and calibration plot were used to assess discrimination and calibration with internal validation.ResultsWith a median follow-up of 25 months, 23 (29.9%) patients experienced BCR within 2 years after RP. Patients experienced BCR had a significant higher PSA at diagnosis (p<0.001), a higher ISUP grade of biopsy (p=0.044), as well as a higher ISUP grade (p=0.001), a higher possibility of T3 diseases (p=0.001) and positive margin (p=0.008) on postoperative pathology. SUVmax, maximum diameter of the index tumor and T stage on preoperative PSMA-ligand PET/CT were significantly associated with BCR (all p<0.01). PSMA-ligand PET/CT-based risk model had a superior discrimination (c-index 78.5%) and good calibration at internal validation. The efficacy of this model in predicting 2-year BCR after RP was better, compared with CAPRA (c-index 66.3%) and D’Amico (c-index 66.2%). The addition of the PSMA-ligand PET/CT-derived variables also improved the efficacy of the existing models in predicting 2-year BCR (C-index of 78.9% for modified CAPRA and 79.3% for modified D’Amico, respectively).ConclusionA PSMA-ligand PET/CT-based risk model showed good efficacy in predicting 2-year BCR after RP, which needed to be validated by further prospective studies.

show abstract

Section: Introductionmentioning

confidence: 94%

Prediction of Biochemical Recurrence After Radical Prostatectomy Based on Preoperative 68Ga-PSMA-11 PET/CT

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…This is particularly true when brachytherapy seeds or metal artifacts created by total hip prostheses are present, which create significant artifact on MRI ( Figure 27 ). [ 68 Ga]-PSMA PET-CT has been shown to be superior to mpMRI in assessing extracapsular extension and equivalent to mpMRI in assessment of seminal vesicle involvement [ 101 ]. In comparison to histopathology on a slice by slice basis, it has been reported that mpMRI underestimates tumor volume significantly when compared to PSMA PET-CT [ 102 ].…”

Section: Urological Malignanciesmentioning

confidence: 99%

PET-CT in Clinical Adult Oncology—IV. Gynecologic and Genitourinary Malignancies

Salem

Fine

Covington

et al. 2022

Cancers

View full text Add to dashboard Cite

Concurrently acquired positron emission tomography and computed tomography (PET-CT) is an advanced imaging modality with diverse oncologic applications, including staging, therapeutic assessment, restaging and longitudinal surveillance. This series of six review articles focuses on providing practical information to providers and imaging professionals regarding the best use and interpretative strategies of PET-CT for oncologic indications in adult patients. In this fourth article of the series, the more common gynecological and adult genitourinary malignancies encountered in clinical practice are addressed, with an emphasis on Food and Drug Administration (FDA)-approved and clinically available radiopharmaceuticals. The advent of new FDA-approved radiopharmaceuticals for prostate cancer imaging has revolutionized PET-CT imaging in this important disease, and these are addressed in this report. However, [18F]F-fluoro-2-deoxy-d-glucose (FDG) remains the mainstay for PET-CT imaging of gynecologic and many other genitourinary malignancies. This information will serve as a guide for the appropriate role of PET-CT in the clinical management of gynecologic and genitourinary cancer patients for health care professionals caring for adult cancer patients. It also addresses the nuances and provides guidance in the accurate interpretation of FDG PET-CT in gynecological and genitourinary malignancies for imaging providers, including radiologists, nuclear medicine physicians and their trainees.

show abstract

“… 33 However, additional studies demonstrate higher sensitivity for extracapsular extension when compared with mpMRI. 34 A retrospective analysis of patients who underwent PSMA-PET and mpMRI prior to treatment found that while mpMRI detected a similar number of prostate cancer when compared with PSMA-PET, the gross tumor volume detected by PSMA-PET was approximately twice that of mpMRI. 35 Thus, of the PET radiotracers available for routine clinical use, PSMA radiotracers offer the most potential for the diagnosis of localized prostate cancer.…”

Section: Pet/ct For Detection Of Localized Prostate Cancermentioning

confidence: 99%

Role of molecular imaging in the detection of localized prostate cancer

Galgano

West

Rais‐Bahrami

2022

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Molecular imaging of prostate cancer continues to grow, with recent inclusion of several positron emission tomography (PET) radiotracers into the recent National Comprehensive Cancer Network guidelines and the US Food and Drug Administration approval of prostate-specific membrane antigen (PSMA)-targeted radiotracers. While much of the work for many of these radiotracers is focused on systemic staging and restaging in both newly diagnosed high-risk prostate cancer and biochemically recurrent disease patients, the potential role of molecular imaging for the detection of localized prostate cancer has not yet been fully established. The primary aim of this article will be to present the potential role for molecular imaging in the detection of localized prostate cancer and discuss potential advantages and disadvantages to utilization of both PET/computed tomography (CT) and PET/magnetic resonance imaging (MRI) for this clinical indication of use.

show abstract

Comparison of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and multi-parametric magnetic resonance imaging (MRI) in the evaluation of tumor extension of primary prostate cancer

Cited by 27 publications

References 25 publications

Prediction of Biochemical Recurrence After Radical Prostatectomy Based on Preoperative 68Ga-PSMA-11 PET/CT

Prediction of Biochemical Recurrence After Radical Prostatectomy Based on Preoperative 68Ga-PSMA-11 PET/CT

PET-CT in Clinical Adult Oncology—IV. Gynecologic and Genitourinary Malignancies

Role of molecular imaging in the detection of localized prostate cancer

Contact Info

Product

Resources

About